Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 374

1.

Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis.

Tanaka Y, Fautrel B, Keystone EC, Ortmann RA, Xie L, Zhu B, Issa M, Patel H, Gaich CL, de Bono S, Rooney TP, Taylor PC.

Ann Rheum Dis. 2019 Apr 30. pii: annrheumdis-2018-214529. doi: 10.1136/annrheumdis-2018-214529. [Epub ahead of print]

2.

Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial.

Sweet K, Dasgupta B, de Vries D, Gourley I, Hsu B, Loza MJ, Taylor PC.

Ann Rheum Dis. 2019 Apr 24. pii: annrheumdis-2019-215183. doi: 10.1136/annrheumdis-2019-215183. [Epub ahead of print] No abstract available.

PMID:
31018960
3.

Right hemisphere occipital rTMS impairs working memory in visualizers but not in verbalizers.

Hilbert S, McAssey M, Bühner M, Schwaferts P, Gruber M, Goerigk S, Taylor PCJ.

Sci Rep. 2019 Apr 19;9(1):6307. doi: 10.1038/s41598-019-42733-6.

5.

How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?-MTX in the Treat-to-Target Strategy.

Taylor PC, Balsa Criado A, Mongey AB, Avouac J, Marotte H, Mueller RB.

J Clin Med. 2019 Apr 15;8(4). pii: E515. doi: 10.3390/jcm8040515.

6.

Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?

Baumgart DC, Misery L, Naeyaert S, Taylor PC.

Front Pharmacol. 2019 Mar 28;10:279. doi: 10.3389/fphar.2019.00279. eCollection 2019. Review.

7.

The Clinical Features, Pathogenesis and Methotrexate Therapy of Chronic Chikungunya Arthritis.

Amaral JK, Taylor PC, Teixeira MM, Morrison TET, Schoen RT.

Viruses. 2019 Mar 22;11(3). pii: E289. doi: 10.3390/v11030289. Review.

8.

Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation.

Bingham CO 3rd, Gaich CL, DeLozier AM, Engstrom KD, Naegeli AN, de Bono S, Banerjee P, Taylor PC.

Trials. 2019 Mar 22;20(1):182. doi: 10.1186/s13063-019-3272-0.

9.

Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients.

Humby F, Lewis M, Ramamoorthi N, Hackney JA, Barnes MR, Bombardieri M, Setiadi AF, Kelly S, Bene F, DiCicco M, Riahi S, Rocher V, Ng N, Lazarou I, Hands R, van der Heijde D, Landewé RBM, van der Helm-van Mil A, Cauli A, McInnes I, Buckley CD, Choy EH, Taylor PC, Townsend MJ, Pitzalis C.

Ann Rheum Dis. 2019 Jun;78(6):761-772. doi: 10.1136/annrheumdis-2018-214539. Epub 2019 Mar 16.

10.

Egocentric processing in the roll plane and dorsal parietal cortex: A TMS-ERP study of the subjective visual vertical.

Willacker L, Dowsett J, Dieterich M, Taylor PCJ.

Neuropsychologia. 2019 Apr;127:113-122. doi: 10.1016/j.neuropsychologia.2019.02.023. Epub 2019 Mar 2.

PMID:
30831119
11.

Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis.

Taylor PC.

Rheumatology (Oxford). 2019 Feb 1;58(Supplement_1):i17-i26. doi: 10.1093/rheumatology/key225.

12.

Cardiovascular Safety During Treatment with Baricitinib in Rheumatoid Arthritis.

Taylor PC, Weinblatt ME, Burmester GR, Rooney TP, Witt S, Walls CD, Issa M, Salinas CA, Saifan C, Zhang X, Cardoso A, González-Gay MA, Takeuchi T.

Arthritis Rheumatol. 2019 Jan 21. doi: 10.1002/art.40841. [Epub ahead of print]

PMID:
30663869
13.

Identification of a cyanobacterial aldehyde dehydrogenase that produces retinoic acid in vitro.

Miles JA, Machattou P, Nevin-Jones D, Webb ME, Millard A, Scanlan DJ, Taylor PC.

Biochem Biophys Res Commun. 2019 Feb 26;510(1):27-34. doi: 10.1016/j.bbrc.2018.12.171. Epub 2019 Jan 17.

PMID:
30660368
14.

MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis.

Peterfy C, DiCarlo J, Emery P, Genovese MC, Keystone EC, Taylor PC, Schlichting DE, Beattie SD, Luchi M, Macias W.

J Rheumatol. 2019 Jan 15. pii: jrheum.171469. doi: 10.3899/jrheum.171469. [Epub ahead of print]

15.

Clinical Pharmacokinetics of a Lipid-Based Formulation of Risperidone, VAL401: Analysis of a Single Dose in an Open-Label Trial of Late-Stage Cancer Patients.

Dilly SJ, Morris GS, Taylor PC, Parmentier F, Williams C, Afshar M.

Eur J Drug Metab Pharmacokinet. 2019 Jan 9. doi: 10.1007/s13318-018-00538-4. [Epub ahead of print]

16.

Preface: Future trends in the field of spondyloarthritis.

Sherlock J, Taylor PC.

Best Pract Res Clin Rheumatol. 2017 Dec;31(6):761-762. doi: 10.1016/j.berh.2018.08.001. Epub 2018 Sep 6. No abstract available.

PMID:
30509438
17.

Patient-reported outcomes and safety in patients undergoing synovial biopsy: comparison of ultrasound-guided needle biopsy, ultrasound-guided portal and forceps and arthroscopic-guided synovial biopsy techniques in five centres across Europe.

Just SA, Humby F, Lindegaard H, Meric de Bellefon L, Durez P, Vieira-Sousa E, Teixeira R, Stoenoiu M, Werlinrud J, Rosmark S, Larsen PV, Pratt A, Choy E, Gendi N, Buch MH, Edwards CJ, Taylor PC, McInnes IB, Fonseca JE, Pitzalis C, Filer A.

RMD Open. 2018 Oct 26;4(2):e000799. doi: 10.1136/rmdopen-2018-000799. eCollection 2018.

18.

Seasonal energy exchange in sea ice retreat regions contributes to differences in projected Arctic warming.

Boeke RC, Taylor PC.

Nat Commun. 2018 Nov 27;9(1):5017. doi: 10.1038/s41467-018-07061-9.

19.

Taking Attention Out of Context: Frontopolar Transcranial Magnetic Stimulation Abolishes the Formation of New Context Memories in Visual Search.

Zinchenko A, Conci M, Taylor PCJ, Müller HJ, Geyer T.

J Cogn Neurosci. 2019 Mar;31(3):442-452. doi: 10.1162/jocn_a_01358. Epub 2018 Nov 20.

PMID:
30457915
20.

Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trials.

Tarp S, Jørgensen TS, Furst DE, Dossing A, Taylor PC, Choy EH, Suarez-Almazor ME, Lyddiatt A, Kristensen LE, Bliddal H, Christensen R.

Semin Arthritis Rheum. 2018 Oct 9. pii: S0049-0172(18)30093-3. doi: 10.1016/j.semarthrit.2018.10.002. [Epub ahead of print]

PMID:
30396592
21.

Protocol for evaluating and implementing a pragmatic value-based healthcare management model for patients with inflammatory arthritis: a Danish population-based regional cohort and qualitative implementation study.

Jørgensen TS, Lykkegaard JJ, Hansen A, Schrøder HM, Stampe B, Sweeney AT, Appel Esbensen B, Bech B, Christensen K, Friis-Mikkelsen E, Røgind H, Lundbak T, Taylor PC, Petersson IF, Wæhrens EE, Kjellberg J, Gudbergsen H, Kristensen LE.

BMJ Open. 2018 Oct 23;8(10):e023915. doi: 10.1136/bmjopen-2018-023915.

22.

Factors influencing the use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice.

Taylor PC, Alten R, Reino JJG, Caporali R, Bertin P, Sullivan E, Wood R, Piercy J, Vasilescu R, Spurden D, Alvir J, Tarallo M.

Patient Prefer Adherence. 2018 Oct 4;12:2007-2014. doi: 10.2147/PPA.S170054. eCollection 2018.

23.

The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis.

Kragstrup TW, Andersen T, Heftdal LD, Hvid M, Gerwien J, Sivakumar P, Taylor PC, Senolt L, Deleuran B.

Front Immunol. 2018 Sep 25;9:2226. doi: 10.3389/fimmu.2018.02226. eCollection 2018. Review.

24.

Characterization and Changes of Lymphocyte Subsets in Baricitinib-Treated Patients With Rheumatoid Arthritis: An Integrated Analysis.

Tanaka Y, McInnes IB, Taylor PC, Byers NL, Chen L, de Bono S, Issa M, Macias WL, Rogai V, Rooney TP, Schlichting DE, Zuckerman SH, Emery P.

Arthritis Rheumatol. 2018 Dec;70(12):1923-1932. doi: 10.1002/art.40680. Epub 2018 Oct 22.

PMID:
30058112
25.

The Development of Complex Digital Health Solutions: Formative Evaluation Combining Different Methodologies.

Lee A, Sandvei M, Asmussen HC, Skougaard M, Macdonald J, Zavada J, Bliddal H, Taylor PC, Gudbergsen H.

JMIR Res Protoc. 2018 Jul 16;7(7):e165. doi: 10.2196/resprot.9521.

26.

Anti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial.

Nanchahal J, Ball C, Davidson D, Williams L, Sones W, McCann FE, Cabrita M, Swettenham J, Cahoon NJ, Copsey B, Anne Francis E, Taylor PC, Black J, Barber VS, Dutton S, Feldmann M, Lamb SE.

EBioMedicine. 2018 Jul;33:282-288. doi: 10.1016/j.ebiom.2018.06.022. Epub 2018 Jul 6.

27.

The Parker Model: Applying a Qualitative Three-Step Approach to Optimally Utilize Input from Stakeholders When Introducing New Device Technologies in the Management of Chronic Rheumatic Diseases.

Jørgensen TS, Skougaard M, Taylor PC, Asmussen HC, Lee A, Klokker L, Svejstrup L, Mountian I, Gudbergsen H, Kristensen LE.

Patient. 2018 Oct;11(5):515-526. doi: 10.1007/s40271-018-0306-8.

28.

Quality of Care in Rheumatoid Disease from the Clinician Perspective: A Modified Delphi Panel Approach.

O'Shea F, Taylor PC, Dickie G, Yaworsky A, Banderas B, Kachroo S.

Rheumatol Ther. 2018 Jun;5(1):87-98. doi: 10.1007/s40744-018-0107-5. Epub 2018 Apr 3.

29.

Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment.

Taylor PC, Alten R, Gomez-Reino JJ, Caporali R, Bertin P, Sullivan E, Wood R, Piercy J, Vasilescu R, Spurden D, Alvir J, Tarallo M.

RMD Open. 2018 Mar 17;4(1):e000615. doi: 10.1136/rmdopen-2017-000615. eCollection 2018.

30.

Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis.

Fautrel B, Alten R, Kirkham B, de la Torre I, Durand F, Barry J, Holzkaemper T, Fakhouri W, Taylor PC.

Rheumatol Int. 2018 Jun;38(6):935-947. doi: 10.1007/s00296-018-4005-5. Epub 2018 Mar 21. Review.

31.

Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study.

Taylor PC, Schiff MH, Wang Q, Jiang Y, Zhuang Y, Kurrasch R, Daga S, Rao R, Tak PP, Hsu B.

Ann Rheum Dis. 2018 May;77(5):658-666. doi: 10.1136/annrheumdis-2017-212496. Epub 2018 Feb 26.

PMID:
29483080
32.

Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies.

Taylor PC, Kremer JM, Emery P, Zuckerman SH, Ruotolo G, Zhong J, Chen L, Witt S, Saifan C, Kurzawa M, Otvos JD, Connelly MA, Macias WL, Schlichting DE, Rooney TP, de Bono S, McInnes IB.

Ann Rheum Dis. 2018 Jul;77(7):988-995. doi: 10.1136/annrheumdis-2017-212461. Epub 2018 Feb 20.

33.

Corrigendum: The RA-MAP Consortium: a working model for academia-industry collaboration.

Cope AP, Barnes MR, Belson A, Binks M, Brockbank S, Bonachela-Capdevila F, Carini C, Fisher BA, Goodyear CS, Emery P, Ehrenstein MR, Gozzard N, Harris R, Hollis S, Keidel S, Levesque M, Lindholm C, McDermott MF, McInnes IB, Mela CM, Parker G, Read S, Pedersen AW, Ponchel F, Porter D, Rao R, Rowe A, Schulze-Knappe P, Sleeman MA, Symmons D, Taylor PC, Tom B, Tsuji W, Verbeeck D, Isaacs JD; RA-MAP Consortium.

Nat Rev Rheumatol. 2018 Jan 24;14(2):119. doi: 10.1038/nrrheum.2018.6.

PMID:
29362468
34.

Subthalamic stimulation, oscillatory activity and connectivity reveal functional role of STN and network mechanisms during decision making under conflict.

Hell F, Taylor PCJ, Mehrkens JH, Bötzel K.

Neuroimage. 2018 May 1;171:222-233. doi: 10.1016/j.neuroimage.2018.01.001. Epub 2018 Jan 4.

PMID:
29307607
35.

Translocator Protein as an Imaging Marker of Macrophage and Stromal Activation in Rheumatoid Arthritis Pannus.

Narayan N, Owen DR, Mandhair H, Smyth E, Carlucci F, Saleem A, Gunn RN, Rabiner EA, Wells L, Dakin SG, Sabokbar A, Taylor PC.

J Nucl Med. 2018 Jul;59(7):1125-1132. doi: 10.2967/jnumed.117.202200. Epub 2018 Jan 4.

36.

The RA-MAP Consortium: a working model for academia-industry collaboration.

Cope AP, Barnes MR, Belson A, Binks M, Brockbank S, Bonachela-Capdevila F, Carini C, Fisher BA, Goodyear CS, Emery P, Ehrenstein MR, Gozzard N, Harris R, Hollis S, Keidel S, Levesque M, Lindholm C, McDermott MF, McInnes IB, Mela CM, Parker G, Read S, Pedersen AW, Ponchel F, Porter D, Rao R, Rowe A, Schulz-Knappe P, Sleeman MA, Symmons D, Taylor PC, Tom B, Tsuji W, Verbeeck D, Isaacs JD; RA-MAP Consortium.

Nat Rev Rheumatol. 2018 Jan;14(1):53-60. doi: 10.1038/nrrheum.2017.200. Epub 2017 Dec 7. Review. Erratum in: Nat Rev Rheumatol. 2018 Jan 24;14 (2):119.

37.

The Odd Couple?-Hardly.

Taylor PC, Jain R.

Rheumatology (Oxford). 2018 Aug 1;57(8):1313-1315. doi: 10.1093/rheumatology/kex205. No abstract available.

PMID:
28977656
38.

Filgotinib for the treatment of rheumatoid arthritis.

Taylor PC, Abdul Azeez M, Kiriakidis S.

Expert Opin Investig Drugs. 2017 Oct;26(10):1181-1187. doi: 10.1080/13543784.2017.1372422. Epub 2017 Aug 29. Review.

PMID:
28838249
39.

A novel quantitative PCR assay for testing bacteria directly from plate cultures using SYBR Green technology.

McIver CJ, Tjandra FA, Er N, Taylor PC.

Pathology. 2017 Oct;49(6):658-660. doi: 10.1016/j.pathol.2017.06.004. Epub 2017 Aug 18. No abstract available.

PMID:
28823753
40.

A novel method to enable PCR testing of bacterial isolates in the BacT/ALERT Microbial Detection System.

McIver CJ, Er N, Stevens R, Taylor PC.

Pathology. 2017 Oct;49(6):656-658. doi: 10.1016/j.pathol.2017.05.012. Epub 2017 Aug 18. No abstract available.

PMID:
28823751
41.

Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis.

Keystone EC, Genovese MC, Schlichting DE, de la Torre I, Beattie SD, Rooney TP, Taylor PC.

J Rheumatol. 2018 Jan;45(1):14-21. doi: 10.3899/jrheum.161161. Epub 2017 Aug 15.

42.

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.

Keystone EC, Taylor PC, Tanaka Y, Gaich C, DeLozier AM, Dudek A, Zamora JV, Cobos JAC, Rooney T, Bono S, Arora V, Linetzky B, Weinblatt ME.

Ann Rheum Dis. 2017 Nov;76(11):1853-1861. doi: 10.1136/annrheumdis-2017-211259. Epub 2017 Aug 10.

43.

Inter-Model Warming Projection Spread: Inherited Traits from Control Climate Diversity.

Hu X, Taylor PC, Cai M, Yang S, Deng Y, Sejas S.

Sci Rep. 2017 Jun 27;7(1):4300. doi: 10.1038/s41598-017-04623-7.

44.

Comparison of the CELLEX™ and UVAR-XTS™ closed-system extracorporeal photopheresis devices in the treatment of chronic graft-versus-host disease.

Whittle RM, Denney H, Chantry AD, Alfred A, Taylor PC.

J Clin Apher. 2017 Dec;32(6):462-473. doi: 10.1002/jca.21541. Epub 2017 Jun 13.

PMID:
28608529
45.

Pro-inflammatory activation of primary microglia and macrophages increases 18 kDa translocator protein expression in rodents but not humans.

Owen DR, Narayan N, Wells L, Healy L, Smyth E, Rabiner EA, Galloway D, Williams JB, Lehr J, Mandhair H, Peferoen LA, Taylor PC, Amor S, Antel JP, Matthews PM, Moore CS.

J Cereb Blood Flow Metab. 2017 Aug;37(8):2679-2690. doi: 10.1177/0271678X17710182. Epub 2017 May 22.

46.

Cognition and higher vestibular disorders: developing tools for assessing vection.

Dowsett J, McAssey M, Dieterich M, Taylor PC.

J Neurol. 2017 Oct;264(Suppl 1):45-47. doi: 10.1007/s00415-017-8449-4. Epub 2017 Mar 14.

PMID:
28293724
47.

The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society.

Alfred A, Taylor PC, Dignan F, El-Ghariani K, Griffin J, Gennery AR, Bonney D, Das-Gupta E, Lawson S, Malladi RK, Douglas KW, Maher T, Guest J, Hartlett L, Fisher AJ, Child F, Scarisbrick JJ.

Br J Haematol. 2017 Apr;177(2):287-310. doi: 10.1111/bjh.14537. Epub 2017 Feb 21.

48.

Plasma Levels of Eicosapentaenoic Acid Are Associated with Anti-TNF Responsiveness in Rheumatoid Arthritis and Inhibit the Etanercept-driven Rise in Th17 Cell Differentiation in Vitro.

Jeffery L, Fisk HL, Calder PC, Filer A, Raza K, Buckley CD, McInnes I, Taylor PC, Fisher BA.

J Rheumatol. 2017 Jun;44(6):748-756. doi: 10.3899/jrheum.161068. Epub 2017 Feb 15.

PMID:
28202745
49.

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.

Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, Yakushin S, Ishii T, Emoto K, Beattie S, Arora V, Gaich C, Rooney T, Schlichting D, Macias WL, de Bono S, Tanaka Y.

N Engl J Med. 2017 Feb 16;376(7):652-662. doi: 10.1056/NEJMoa1608345.

50.

A chemical genomics approach to drug reprofiling in oncology: Antipsychotic drug risperidone as a potential adenocarcinoma treatment.

Dilly SJ, Clark AJ, Marsh A, Mitchell DA, Cain R, Fishwick CWG, Taylor PC.

Cancer Lett. 2017 May 1;393:16-21. doi: 10.1016/j.canlet.2017.01.042. Epub 2017 Feb 8.

Supplemental Content

Loading ...
Support Center